SCHEMBL2719871

SCHEMBL2719871

COCC(=O)NCc1ccccc1

nearest known ligand 0.73

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.67
HPGD P15428 2/20 0.67
SMN1; SMN2 Q16637 1/20 0.62
NPC1 O15118 1/20 0.59
GAA P10253 1/20 0.59
MAPT P10636 2/20 0.59
RAB9A P51151 1/20 0.58
MEN1 O00255 3/20 0.58
HTT P42858 1/20 0.57
ALDH1A1 P00352 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
PKM P14618 1/20 0.56
TSHR P16473 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8562123 0.90 HSD17B10 (0.62) KMT2AHPGDSMN1; SMN2NPC1GAA
SCHEMBL17358642 0.88 KMT2A (0.57) KMT2AHPGDSMN1; SMN2NPC1GAA
SCHEMBL14337377 0.86 GAA (0.64) KMT2ASMN1; SMN2GAAMAPTMEN1
SCHEMBL27941201 0.84 KMT2A (0.62) KMT2AHPGDGAAALDH1A1
SCHEMBL24600228 0.84 HSD17B10 (0.56) KMT2AHPGDSMN1; SMN2NPC1GAA
SCHEMBL12615941 0.84 ALDH1A1 (0.54) KMT2AHPGDSMN1; SMN2NPC1MAPT
SCHEMBL14679137 0.84 KMT2A (0.57) KMT2AHPGDSMN1; SMN2NPC1RAB9A
SCHEMBL28313089 0.82 NR1H4 (0.56) KMT2AHPGDNPC1MEN1
SCHEMBL10433480 0.82 KMT2A (0.65) KMT2AHPGDSMN1; SMN2GAAMAPT
SCHEMBL6956890 0.82 SPR (0.70) SMN1; SMN2NPC1MAPTRAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2629889-B1 RUTHENIUM COMPLEXES AND THEIR USES IN PROCESSES FOR FORMATION AND/OR HYDROGENATION OF ESTERS, AMIDES AND DERIVATIVES THEREOF YEDA RES & DEV (IL) 2019-04-03 EP claimed
US-20170283447-A1 RUTHENIUM COMPLEXES AND THEIR USES AS CATALYSTS IN PROCESSES FOR FORMATION AND/OR HYDROGENATION OF ESTERS, AMIDES AND RELATED REACTIONS YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2017-10-05 US claimed
EP-3188832-A1 RUTHENIUM COMPLEXES AND THEIR USES AS CATALYSTS IN PROCESSES FOR FORMATION AND/OR HYDROGENATION OF ESTERS, AMIDES AND RELATED REACTIONS Yeda Research and Development Co., Ltd. (IL) 2017-07-12 EP claimed
US-9290441-B2 Use of ruthenium complexes for formation and/or hydrogenation of amides and related carboxylic acid derivatives YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2016-03-22 US claimed
WO-2016035080-A1 RUTHENIUM COMPLEXES AND THEIR USES AS CATALYSTS IN PROCESSES FOR FORMATION AND/OR HYDROGENATION OF ESTERS, AMIDES AND RELATED REACTIONS YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2016-03-10 WO claimed
EP-2629889-A2 NOVEL RUTHENIUM COMPLEXES AND THEIR USES IN PROCESSES FOR FORMATION AND/OR HYDROGENATION OF ESTERS, AMIDES AND DERIVATIVES THEREOF Yeda Research and Development Co. Ltd. (IL) 2013-08-28 EP claimed
US-20120253042-A1 USE OF RUTHENIUM COMPLEXES FOR FORMATION AND/OR HYDROGENATION OF AMIDES AND RELATED CARBOXYLIC ACID DERIVATIVES YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2012-10-04 US claimed
WO-2012052996-A2 NOVEL RUTHENIUM COMPLEXES AND THEIR USES IN PROCESSES FOR FORMATION AND/OR HYDROGENATION OF ESTERS, AMIDES AND DERIVATIVES THEREOF YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2012-04-26 WO claimed
EP-0263506-B1 ANTICONVULSANT COMPOSITION CONTAINING AMINO ACID DERIVATIVE AND USE OF SAID AMINO ACID DERIVATIVE RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1993-08-04 EP claimed
EP-0263506-A2 Anticonvulsant composition containing amino acid derivative and use of said amino acid derivative RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1988-04-13 EP claimed
US-12145139-B2 Manganese based complexes and uses thereof for homogeneous catalysis YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2024-11-19 US disclosed
CN-112313239-B Immobilized ruthenium-TRIPHOS catalysts for selective hydrogenation of amides 伊士曼化工公司 2024-04-02 CN disclosed
US-20230372915-A1 MANGANESE BASED COMPLEXES AND USES THEREOF FOR HOMOGENEOUS CATALYSIS YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2023-11-23 US disclosed
EP-3188832-B1 RUTHENIUM COMPLEXES AND THEIR USES AS CATALYSTS IN PROCESSES FOR FORMATION AND/OR HYDROGENATION OF ESTERS, AMIDES AND RELATED REACTIONS YEDA RES & DEV (IL) 2023-10-04 EP disclosed
CN-112105623-B Molecular catalysts for selective hydrogenolysis of amides 伊士曼化工公司 2023-09-12 CN disclosed
US-7378414-B2 Viricides for infections caused by an RNA-containing virus; enzyme inhibitors for a hepatitis C virus (HCV) polymerase; inhibiting HCV viral replication; liver cirrhosis; e. g., 3-(1,1-dioxido-4H-1,2,4-benzothiadiazin-3-yl)-4-hydroxy-1,1-dipropyl-2(1H)-naphthalenone ABBOTT LABORATORIES (US) 2008-05-27 US disclosed
US-20050176742-A1 Novel compounds and their use in therapy SOLVAY PHARMACEUTICALS B.V. (NL) 2005-08-11 US disclosed
US-20050038053-A1 Novel compounds and their use in therapy SOLVAY PHARMACEUTICALS B.V. (NL) 2005-02-17 US disclosed
EP-0263506-B1 ANTICONVULSANT COMPOSITION CONTAINING AMINO ACID DERIVATIVE AND USE OF SAID AMINO ACID DERIVATIVE RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1993-08-04 EP disclosed
EP-0263506-A2 Anticonvulsant composition containing amino acid derivative and use of said amino acid derivative RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1988-04-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230372915-A1 MANGANESE BASED COMPLEXES AND USES THEREOF FOR HOMOGENEOUS CATALYSIS ADH1C, OTC, MLEC KMT2A 843/4885HPGD 2241/4885SMN1; SMN2 975/4885
US-20120253042-A1 USE OF RUTHENIUM COMPLEXES FOR FORMATION AND/OR HYDROGENATION OF AMIDES AND RELATED CARBOXYLIC ACID DERIVATIVES ADH5, ADH1C, ADH1A KMT2A 3046/4885HPGD 524/4885SMN1; SMN2 4479/4885
US-12145139-B2 Manganese based complexes and uses thereof for homogeneous catalysis ADH1C, OTC, MLEC KMT2A 843/4885HPGD 2241/4885SMN1; SMN2 975/4885
US-20050176742-A1 Novel compounds and their use in therapy HSD17B11, HSD17B2, HSD17B1 KMT2A 2945/4885HPGD 96/4885SMN1; SMN2 3338/4885
US-20170283447-A1 RUTHENIUM COMPLEXES AND THEIR USES AS CATALYSTS IN PROCESSES FOR FORMATION AND/OR HYDROGENATION OF ESTERS, AMIDES AND RELATED REACTIONS ADH1A, ADH1C, ADH5 KMT2A 2599/4885HPGD 2746/4885SMN1; SMN2 4871/4885
US-20050038053-A1 Novel compounds and their use in therapy HSD17B11, HSD17B2, HSD17B1 KMT2A 2945/4885HPGD 96/4885SMN1; SMN2 3338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.